Swissmedic - Swiss Agency for Therapeutic Products

06/18/2026 | News release | Distributed by Public on 06/18/2026 02:10

Revised annex 3a TPLRO

18.06.2026

On 1 July 2026, the revised Annex 3a of the Ordinance on the Licensing Requirements for Therapeutic Products (TPLRO) will enter into force. Polysorbates are newly listed as excipients of particular interest for parenteral and topical use.

Polysorbates are widely used as excipients, particularly in biological and biotechnological medicinal products.

Marketing authorisation holders of human medicinal products must review their product information texts and packaging materials for compliance with the new requirements and submit any necessary amendments to Swissmedic (variation E.100 b), type IB).

Swissmedic - Swiss Agency for Therapeutic Products published this content on June 18, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 18, 2026 at 08:10 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]